Amgen R&D chief Sean Harper hits the exits with a one-way ticket to early-stage biotech
Sean Harper is joining the migration out of big biopharma and into the world of emerging biotechs.
The head of R&D at Amgen has turned …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
